Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Characteristics Patients
Entered n = 97
Median age (years) (range) 46 (25-73)
Age > 65 years 12 (12.4%)
Age < 35 years 8 (8.2%)
Stage 4 at primary diagnosis 24 (24.7%)
Grade 3 tumour 64 (66%)
Invasive ductal carcinoma 81 (83.5%)
Positive hormone receptor status 41 (42.3%)
Visceral metastases 73 (75.3%)
Median metastatic sites (sites) (range) 2 (1-6)
   Lung 36
   Liver 49
   Bones 51
   Lymph nodes 37
   Soft tissue 48
   Skin 16
   Brain (before trastuzumab) 1
   Others 3
More than one metastatic site 78 (80.4%)
Adjuvant chemotherapy 67 (69.1%)
   Anthracyycline based 37
   Taxane based 2
   Combination anthracyclines/taxanes 22
Adjuvant endocrine therapy 26 (26.8%)
Adjuvant trastuzumab 9 (9.3%)
Duration adjuvant trastuzumab (median) (range) 10 (4-24)
Palliative treatment other than trastuzumab-based 35 (36.1%)
Second-line combination  
   Taxanes 21
   Vinorelbine 30
   Capecitabine 23
   Gemcitabine 12
   Anthracyclines 5
   Others 6
Trastuzumab beyond second-line 55 (56.7%)
Lapatinib beyond second-line trastuzumab 14 (14.4%)